Dowden Nathan J's Form 4 filing
Entrada Therapeutics, Inc. (TRDA) · filed Sep 10, 2024
- Accession no.
- 0001689375-24-000054
- Filed
- Sep 10, 2024
- Trade date
- Sep 6-9, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $34.8K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Dowden Nathan JCIK 0001873392 | Officer (President & COO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 6, 2024 | Common Stock | SSaleDisposed | −399 | $15.19 | −$6,060.81 | 127,900 | Direct | |
| Sep 9, 2024 | Common Stock | SSaleDisposed | −1,904 | $15.07 | −$28,693.28 | 125,996 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.